Jesper Brandgaard, CFO of Danish drug producer, Novo Nordisk, tells CNBC that another steady quarter from their insulin franchise contributed to a good overall third quarter.
Data is a real-time snapshot *Data is delayed at least 15 minutes Market Data Terms of Service
Global Business and Financial News, Stock Quotes, and Market Data and Analysis
More Comments
ADD COMMENTS
PREVIEW COMMENT